Medline ® Abstract for Reference 132
of 'Pharmacotherapy of allergic rhinitis'
Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis.
Patel P, Philip G, Yang W, Call R, Horak F, LaForce C, Gilles L, Garrett GC, Dass SB, Knorr BA, Reiss TF
Ann Allergy Asthma Immunol. 2005;95(6):551.
BACKGROUND: Perennial allergic rhinitis (PAR) is a persistent allergic inflammation of the upper respiratory tract due to year-round allergen exposure.
OBJECTIVE: To evaluate the leukotriene receptor antagonist montelukast for the treatment of PAR.
METHODS: Protocol 265 was a 2-arm study performed during the winter. After a placebo run-in period, adults with perennial allergen sensitivity and active symptoms of PAR were randomized to receive 10 mg of montelukast (n=1002) or placebo (n=990) once daily during a 6-week, double-blind, active-treatment period. The primary end point was the daytime nasal symptoms score, defined as the average of scores for nasal congestion, rhinorrhea, and sneezing rated daily by patients.
RESULTS: Statistically significant improvements in PAR symptoms were seen in patients treated with montelukast. Their daytime nasal symptoms scores were reduced during treatment compared with those of theplacebo group: the difference between treatments in least squares mean change from baseline was -0.08 (95% confidence interval [CI], -0.12 to -0.04; P<.001). Montelukast treatment also improved global evaluations of allergic rhinitis by patients and Rhinoconjunctivitis Quality of Life Questionnaire scores: differences vs the placebo group were -0.15 (95% CI, -0.27 to -0.04; P<.01) and -0.15 (95% CI, -0.24 to -0.06; P<.001), respectively. Other end points that showed statistically significant improvement with montelukast treatment were nighttime symptoms and each of the 4 nasal symptoms (congestion, rhinorrhea, sneezing, and itching). The treatment effects of montelukast were stable and persistent during the entire 6 weeks of treatment.
CONCLUSION: Montelukast provided statistically significant relief of PAR symptoms during 6 weeks of treatment.
Allied Research International, Mississauga, Ontario, Canada. PPatel@allied-research.com